siRNA as a Potential Therapy for COVID-19

Area of Science:

• Virology
• Molecular Biology
• Biotechnology

Background:

• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19, a global pandemic with significant health and economic impacts.
• No specific antiviral treatment currently halts the pandemic, necessitating the exploration of novel therapeutic strategies.
• Coronaviruses, including SARS-CoV-2, possess a positive-sense, single-stranded RNA genome, making them susceptible to RNA interference.

Purpose of the Study:

• To evaluate RNA interference (RNAi) as a potential prophylactic and therapeutic approach against SARS-CoV-2.
• To highlight the suitability of small interfering RNA (siRNA) technology for controlling current and future coronavirus outbreaks.
• To leverage existing knowledge of coronavirus genomes for optimized siRNA targeting.

Main Methods:

• Utilizing small interfering RNA (siRNA) molecules, which are 21-29 nucleotide duplexes.
• Employing the RNAi mechanism for targeted gene silencing via complementary destruction of viral messenger RNA (mRNA) in the cytoplasm.
• Analyzing the conserved sequences within coronavirus genomes to optimize siRNA design and prevent viral escape mutations.

Main Results:

• Previous studies demonstrated the efficacy of siRNA against SARS-CoV and MERS-CoV in vitro and in vivo.
• Advances in siRNA technology have led to successful commercial product approvals, indicating platform maturity.
• Knowledge of coronavirus genome structure facilitates the identification of conserved target sequences for effective siRNA intervention.

Conclusions:

• RNA interference (RNAi) presents a viable therapeutic and prophylactic option for managing SARS-CoV-2 and future coronavirus pandemics.
• Optimized siRNA targeting, based on conserved viral sequences, can effectively combat viral RNA and mitigate mutation-driven escape.
• The established success of siRNA technology provides a strong foundation for its application against COVID-19.